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Abstract
Objective
This study aims to assess whether a standard intervention package of cardiovascular dis-
ease (CVD) care was being delivered effectively, and if it was associated with improved life-
style and biomedical indicators.
Methods
In rural China, we implemented a pragmatic cluster randomized controlled trial for 12
months, randomized at the township hospital level, and compared with usual care. Interven-
tion case management guideline, training and performance monitoring meeting and patient
support activities were designed to fit within the job description of family doctors in the town-
ship hospitals and comprised: 1) prescription of a standardised package of medicines tar-
geted at those with hypertension or diabetes; 2) advice about specific lifestyle interventions;
and 3) advice about medication adherence. Participants were 50–74 years old, had hyper-
tension and CVD risk scores >20% or diabetes, but were excluded if a history of severe
CVD events. We also randomly selected 100 participants from six selected clusters per arm
as a panel to collect intermediate biomedical indicators over time.
Results
A total of 28,130 participants, in 33 intervention and 34 control township hospitals, were
recruited. Compared with the control arm, participants in the intervention arm had substan-
tially improved prescribing rates of anti-hypertensives, statins and aspirin (P<0.001), and
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had higher medication taking rates of aspirin and statins (P<0.001). Mean systolic and dia-
stolic blood pressures were similar across both arms (0.15 mmHg, P = 0.79, and 0.52
mmHg, P = 0.05, respectively). In the panel, (950) rates of smoking (OR = 0.23, P = 0.02)
and salt intake (OR = 2.85, P = 0.03) were significantly reduced in the intervention versus
control arms, but there were no statistically significant improvement over the 12 month fol-
low-up period in biomedical indicators (P>0.05).
Conclusion
Implementation of the package by family doctors was feasible and improved prescribing and
some lifestyle changes. Additional measures such as reducing medication costs and patient
education are required.
Trial registration
Current Controlled Trials ISRCTN58988083
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide.
Primary prevention of CVD requires adequately controlled blood pressure, diabetes mellitus
and hyperlipidaemia as well as a reduction in obesity, smoking and alcohol consumption [1].
Hypertension is responsible for over 50% of strokes and 25% of CVD worldwide [2]. The
global burden of diabetes is no less challenging with over 400 million people estimated to have
the disease, half of whom are undiagnosed, with complications being a major cause of disabil-
ity and reduced quality of life [3]. Every year over nine million people die from hypertension-
related disease and nearly five million die from diabetes, with most of this mortality being pre-
mature [4]. Despite this huge disease burden, access to prevention and treatment remains out
of reach for most people in low- and middle-income countries [5].
In China, CVD accounts for 38% of total mortality [6]. In 2010, the country had an estimated
266 million people with hypertension, 180 million with hyperlipidaemia, 92 million with diabe-
tes and 240 million who were overweight [7]. As a result of these risk factors CVD events are
predicted to increase by 23% from 2010 to 2030, resulting in 21.3 million additional CVD events
and 7.7 million deaths [8]. Despite this heavy burden of disease the health services generally fail
to detect and manage hypertension, diabetes and other CVD risk factors effectively. Surveys in
China demonstrate that only 24% of hypertensive patients knew their condition, only 19% were
on therapy and less than 5% had their blood pressure adequately controlled [9]. Adherence to
medication is a major issue as less than 20% of hypertensive patients took anti-hypertensive
medication in a timely way [10]. Similarly, a national survey in 2010 showed a Type II diabetes
prevalence of 12% among adults, with only 26% receiving treatment [11].
CVD risk reduction cannot be achieved by treating hypertension or diabetes as separate dis-
eases [12] [13]. A more comprehensive approach is needed. Patients with a calculated 10-year
CVD risk (i.e. risk of coronary heart disease or stroke) of 20% or above are in need of thera-
peutic and lifestyle interventions delivered predominantly at the primary care level [14]. Stud-
ies have shown that medications such as modern anti-hypertensives, statins, and aspirin,
especially in low-dose combinations, can substantially reduce CVD events [15, 16]. Healthy
lifestyle interventions may have moderate effects in CVD risk reduction [1]. Smoking cessation
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and increased exercise are important in reducing long-term morbidity and mortality [17, 18].
Salt reduction or substitution can lead to reduced blood pressure [19], with a study in China
showing that salt substitution reduced mean systolic blood pressure by 3.7 mmHg [20].
In 2009 China embarked on a series of health reforms aiming to build a primary care ori-
ented system. Key components include the provision of a universal health insurance package
and basic public health services, including detection and management of hypertension and
diabetes at the community level. In rural areas, the township hospital is responsible for provid-
ing clinical care to the resident population, including public health activities such as the fol-
low-up of patients according to national hypertension and diabetes guidelines [10]. However,
the management of hypertension and diabetes is not integrated, and there is no specific medi-
cation adherence support or systematic health education [21]. After developing a suitable
intervention of a comprehensive approach, we initiated a pragmatic, cluster-randomized con-
trolled trial (cRCT) in the primary care setting of rural China to assess the health effects of the
interventions over two years. Here we aimed to assess whether these interventions of the trial
were being delivered over a 12-month period, were associated with reduced blood pressure,
and, in a smaller sub-group, whether there were any differences in a range of intermediate out-
comes at 12 months.
Materials and methods
Ethics statement
This study was approved by the Ethics Review Board of the University of Leeds, UK (reference
HSLTLM/12/010) and the Ethics Committee of Zhejiang Provincial Centre for Disease Con-
trol and Prevention, China (reference 18/06/2012). All participants have given written
informed consent before participating in the study.
Study design and participants
This study was based on an on-going, two-arm, parallel-group, cluster-randomized controlled
trial that aims to answer to what extent the intervention strategies have been implemented.
This was designed as a pragmatic trial as i) eligibility criteria for hospitals and patients were
broad and inclusive to represent typical rural populations; ii) medications were not freely pro-
vided but were covered up to 30% by the rural health insurance scheme; and iii) delivery of the
services was embedded within the routine job descriptions of family doctors. To assess delivery
of interventions we compared the following outcomes between intervention and control town-
ships: i) the prescribing and taking of medications at quarterly intervals over 12 months; and
ii) blood pressure readings at quarterly intervals over 12 months. To assess intermediate out-
comes at 12 months we selected a sub-group panel in which we measured medication adher-
ence using Morisky questionnaire, healthy lifestyles, changes in body mass index (BMI),
glycated hemoglobin levels (HbA1c) and lipid profiles at 12 months compared with those
found at baseline (S1 Table).
Three counties located in central Zhejiang province were selected on the basis that their
townships hospitals had electronic health records and agreed to participate in the trial [22]. We
excluded one township whose hospital was used for a pilot study. In each township we recruited
patients aged 50 to 74 years who held permanent residence in the township and were either
hypertensive with a 10-year CVD risk of 20% or higher calculated using the Asian Equation [23],
based on information available in the electronic health records [10], or had a recorded medical
history of Type 2 diabetes mellitus. All eligible participants were identified from existing health
records. We excluded patients with mental health problems, physical disabilities, history of
severe CVD events, or other severe diseases. We also excluded patients who were hospitalized
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during recruitment; patients who had serious adverse effects to the recommended drugs; those
whose diastolic blood pressure were lower than 60 mmHg; or those who had high risk of CVD
but did not have hypertension or diabetes; or those who declined to participate in the trial.
Potentially eligible participants were asked to visit the township hospital where they were
assessed by family doctors for eligibility criteria, consulted about their willingness to participate
in the study and invited to provide informed written consent. Patients in Zhejiang were used to
visit their own township hospitals based on health insurance regulations, also due to the familiar-
ity of doctors, thus the potential for cross contamination is low [24]. Participant recruitment
lasted from December 2013 to May 2014, and the participants had been followed up for 12
months when this analysis was conducted. The authors confirm that all ongoing and related tri-
als for this intervention are registered (S1 File).
Sample size
The sample size for the whole study group was based on the primary outcome measure: the
CVD event rate. We assumed the intervention would lead to a relative reduction of at least
20% from the current CVD event rate of 5% within two years, based on published values. We
estimated to require 32 clusters per arm with 450 participants per cluster to detect such a dif-
ference with 90% power, assuming a coefficient of variation of 0.15 and testing at the 5% level.
The sample size calculation for the panel sub-group was conducted to power the detection
of effects in outcomes measured from the panel patients’ blood samples: HbA1c, total serum
cholesterol (TC) and low-density lipoprotein (LDL) levels. This sample size was based on
detecting changes in TC, because it was expected to display the smallest change. Based on pilot
data and values from the literature, and assuming just one-third of patients took their statins,
we expected a 6% relative reduction in the level of TC. We estimated we required 6 clusters per
arm to detect this change with 90% power, with 100 participants per cluster and 10% loss to
follow-up, assuming an intracluster correlation coefficient of 0.01, and testing at the 5% level.
Full details of the sample size calculations are given in the trial protocol [22].
Randomization and masking
An independent biostatistician randomly allocated eligible township hospitals to intervention
or control arms in a 33:34 ratio using sequential numbers without stratification. Allocation
took place after subject recruitment. All eligible participants in each township received the
study treatment allocated to their township hospital. Blinding was not feasible for patients or
providers. Written informed consent was obtained from both hospital directors and individu-
als. For the panel, six clusters (100 participants per cluster) were randomly selected from each
arm.
Intervention arm
The intervention case management guideline, training and performance monitoring meeting
and patient support activities were designed to fit within the job description of family doctors
in the township hospitals. These comprised: 1) prescription of a standardised package of highly
effective medicines targeted at those with hypertension or with diabetes; 2) advice about spe-
cific lifestyle interventions; and 3) advice about medication adherence [22]. Intervention activ-
ities were documented in a deskguide, which included a clinical treatment algorithm and
information on the use of recommended medicines (on the essential medicine list); healthy
lifestyle education; medication adherence support; and how to change and replace existing
medicines if necessary [22]. Training of trainers on the use of the deskguide was provided for
senior doctors on a half-day course annually. These doctors then became trainers in their own
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township hospitals and conducted initial and refresher trainings quarterly. In addition, the
township hospitals discussed the performance and improvement strategies in their monthly
internal meetings based on the feedback of performance indicators sent by local CDCs.
All hypertensive patients in this trial had high risk of CVD, thus the clinical treatment algo-
rithm recommended, for all hypertensive patients in the trial, prescribing a standard combination
[25] of two anti-hypertensives (two different kinds selected from thiazide-diuretics, calcium-
channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or
beta-blockers, according to the Chinese Hypertension Guideline) [26], a statin, and a low dose of
aspirin. Patients with diabetes only were prescribed a standard combination of one anti-hyper-
tensive, a statin, and a low dose of aspirin, plus their anti-diabetic medicines if any. Patients
already on other anti-hypertensive medicines were advised to switch to the modern medicines in
the standardised packages. All doctors were educated of side effects and contradictions of the
medicines, such as not giving aspirin to haemorrhagic patients, and how to detect the early sign
of any side effects. According to the health insurance policies, patients could purchase their medi-
cations from the hospital pharmacy or any qualified street pharmacies using doctor prescriptions
according to health insurance policies. Doctors were trained to recommend the medications that
were prescribed but not actually taken in the following consultations.
Participants were followed up by their family doctor monthly in the township hospitals or
during the doctor’s home visit, and were reminded of follow-up appointment through phone
call/SMS. The consultation included health education, focusing on smoking cessation, healthy
eating, salt reduction, and reduction in alcohol consumption. Patients were assisted to select a
family treatment supporter who received advice on how to provide support at home to
improve medication and lifestyle change adherence (S1 Text).
Control arm
In the control arm, management of hypertension and diabetes continued conventional clinical
consultations, with treatment provided according to the individual family doctor’s existing knowl-
edge and discretion (including of current national guidelines if aware of them). No specific medi-
cation adherence support was provided, and health education, if any, was non-systematic.
Data collection
We aimed to follow up all patients at least once per quarter, with follow up data collected dur-
ing all consultations. During consultations doctors recorded patient prescriptions and their
actual intake of medications. They also recorded patients’ blood pressures, measured using
mercury sphygmomanometers after patients had sat for five minutes. In both arms doctors
entered data on patients’ blood pressure, height and weight into the routine internet-based
public health management information system. Additionally, those participants selected for
the panel population underwent an examination, where doctors recorded their BMI, blood
pressure, and levels of HbA1c, TC and LDL at baseline, 12 and 24 months after randomization
[22]. All laboratory specimens and tests results were quality assured at the provincial central
reference laboratory. Patients were also interviewed regarding their smoking status, alcohol
consumption, physical exercise, and drug adherence. This data was recorded in a parallel inter-
net-based trial management system designed for family doctors.
Outcomes
The primary outcome of the trial is the incidence of severe CVD events (i.e., coronary heart
disease and stroke) over 36 months of follow-up recorded by Zhejiang’s CVD surveillance
system, which will not be reported in this process evaluation paper. In this study we report
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descriptively quarterly outcomes for rates of prescribing and actual drug-taking of recom-
mended highly effective medicines, and mean systolic and diastolic blood pressure (mmHg),
for all participants. We also analyze changes in these outcomes between baseline and 12
month follow-up. Similarly, in the panel population we report and analyze changes in patient
intermediate outcomes at baseline and 12 months for levels of HbA1c (%), TC (mmol/L) and
LDL (mmol/L), as well as rates of smoking and alcohol consumption, salt intake, exercise,
BMI, and participant adherence to medications (i.e., whether taking medicines timely and
with full dosage among patients who have taken medicines) using the Morisky scale, where
achieving 6–8 within a scale of 0–8 was regarded as good adherence [27]. Control of hyperten-
sion was defined as both a systolic pressure 140 mmHg and a diastolic pressure 90
mmHg. Other outcomes listed in the protocol will be reported in a qualitative process evalua-
tion paper to be published elsewhere.
Statistical analysis
All data from the internet-based management system were exported to SPSS1 20.0 (Chicago,
USA) and analyzed using SAS1 9.4 (Cary NC, USA). Data were analyzed according to the
randomized allocation of their township, and irrespective of their adherence to the protocol.
Another biostatistician (MKCC) who was responsible for data analysis was blinded to the
treatment allocation. Descriptive analyses of means, medians and proportions were used to
report baseline socio-demographic and clinical information. For the panel sub-group, the
intervention effects on continuous 12 month outcomes (i.e. systolic and diastolic blood pres-
sure, HbA1c, TC, LDL and BMI) were analyzed using linear mixed-effect models adjusted for
clustering (i.e. a random effect of township hospital), and baseline covariates, namely age, gen-
der, education levels, and annual incomes. The intervention effects on binary 12 month out-
comes, such as changes in smoking rates, were analyzed using mixed-effects logistic regression
models adjusting for clustering and the same demographic/socio-economic factors. The effects
of the intervention on 12 month systolic and diastolic blood pressures in the whole population
group were analyzed using linear mixed-effect models adjusting for clustering, and other
potentially confounding covariates as above. Hypothesis testing was two-sided and at the 5%
level. Cases with missing outcome or covariate data were excluded. Standard model assump-
tions, such as homoscedasticity and normality of errors/random effects, were assessed to
ensure models were valid.
Results
Delivery of interventions for the whole study group
All the 67 eligible township hospitals are currently participating in the study. A total of 28,130
hypertensive or diabetes patients met the inclusion criteria and were enrolled between Decem-
ber 2013 and May 2014. Demographic and clinical characteristics at baseline are shown in
Table 1. In each arm, the majority of patients were 60 years or older, married, had an education
level of primary school or lower, and had an average per capita annual income of RMB 12,900
(USD 2,150). In each arm, around two thirds of patients had hypertension (with or without
diabetes) and one third had diabetes alone. There were no substantial imbalances in character-
istics between arms at baseline. At 12 months, all 67 clusters were successfully followed up,
with 12,270 (92%) in the intervention arm and 13,118 (90%) in the control arm successfully
followed up and included in the analysis. Loss to follow-up was similar between the interven-
tion and control arms (Fig 1).
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Prescribing and taking of medications
Results for all hypertensive patients are given in Fig 2A–2D. Prescription of two anti-hyperten-
sive drugs at baseline was low, at around 23% in each arm. At 12 months (quarter 4) follow-
up, around 50% of patients were prescribed two anti-hypertensives in the intervention arm
compared with 20% in the control arm (OR = 3.55, 95% CI: 3.31 to 3.80, P<0.001). Similarly,
aspirin and statin prescription and taking rates were very low at baseline, at less than 1.1% in
each arm. At 12 months, around 91% were prescribed aspirin and 87% prescribed statins in
the intervention arm compared with around 1.7% and 1.0% respectively in the control arm
(OR = 565.77, 95% CI: 469.12 to 682.33, P<0.001 and OR = 656.24, 95% CI: 523.36 to 822.85,
P<0.001, respectively). At 12 months, the drug-taking rates of two anti-hypertensives were
similar for intervention and control arms at around 24% (OR = 1.06, 95% CI: 0.98 to 1.14,
P = 0.151), while drug-taking rates of aspirin and statin were much higher in the intervention
arm (13% and 7% respectively) than in the control arm (1.7% and 0.6% respectively)
(OR = 8.85, 95% CI: 7.37 to 10.63, P<0.001 and OR = 11.79, 95% CI: 8.76 to 15.87, P<0.001).
Results for patients with diabetes only are given in Fig 3A–3D. As with anti-hypertensive
drugs, prescription rates for aspirin and statins were similar between the two arms at baseline.
At 12 months, around 85% of patients were prescribed an anti-hypertensive in the intervention
arm compared with 33% in the control arm (OR = 11.41, 95% CI: 10.24 to 12.71, P<0.001),
and around 90% were prescribed aspirin and 86% prescribed a statin in the intervention arm
compared with around 1.1% and 1.7% respectively in the control arm (OR = 806.98, 95% CI:
597.55 to 1089.79, P<0.001 and OR = 360.86, 95% CI: 282.59 to 460.81, P<0.001). At 12
months, drug-taking rates of one anti-hypertensive were similar for intervention and control
arms, at around 32% (OR = 0.98, 95% CI: 0.89 to 1.07, P = 0.596), while drug-taking rates of
aspirin and a statin were higher in the intervention arm (8% and 5% respectively) than in the
Table 1. Demographic, socioeconomic and disease characteristics of patients recruited in the trial.
Intervention group
N or mean (% or SD)
Control group
N or mean (% or SD)
Total
N or mean (% or SD)
Number of patients 13385 14745 28130
Age 64.3 (6.3) 64.3 (6.1) 64.3 (6.2)
Gender
Male 6443 (48.1) 7316 (49.6) 13759 (48.9)
Female 6942 (51.9) 7429 (50.4) 14371 (51.1)
Married1 11618 (98.1) 12763 (98.4) 24381 (98.3)
Education1
Primary (6 years) 10356 (77.6) 11070 (75.4) 21426 (76.5)
High school (7–12 years) 2691 (20.2) 3234 (22.0) 5925 (21.1)
College and above (12 years) 290 (2.2) 382 (2.6) 672 (2.4)
Annual household income (RMB) 35,300 (40,400) 39,800 (51,000) 37,700 (46,500)
Annual per capita income (RMB) 12,000 (11,800) 13,700 (19,500) 12,900 (16,400)
Hypertension and diabetes diagnoses1
Including hypertension 8781 (65.7) 9087 (62.2) 17868 (63.9)
Only diabetes 4585 (34.3) 5521 (37.8) 10106 (36.1)
SD: Standard Deviation, RMB: Renminbi at the rate of 1USD = 6RMB in 2013/14
1 Missing values were excluded for proportion calculations: 1542 (11.5%) and 1774 (12.0%) missing values in intervention and control group for marriage
status; 48 (0.4%) and 59 (0.4%) missing values in intervention and control group for education; 19 (0.1%) and 137 (0.9%) missing values in intervention and
control group for hypertension and diabetes diagnoses.
https://doi.org/10.1371/journal.pone.0183169.t001
Comprehensive intervention package for hypertension and diabetes in China
PLOS ONE | https://doi.org/10.1371/journal.pone.0183169 August 16, 2017 7 / 19
Fig 1. Trial profile. a. Eligible subjects included those 1) aged 50–74; 2) with a calculated 10-year CVD risk20% and having hypertension; or 3)
diagnosed as diabetic. Subjects excluded were those who had 1) mental diseases; 2) cancers; 3) acute coronary heart disease or had previously suffered
stroke; 4) diastolic blood pressure <60 mmHg; or those who were 5) out of town for more than 3 months or non-locals; 6) urban residents; or those who 7)
couldn’t take recommended medicines due to other severe diseases such as cancer. b. Subjects who did not sign consent forms were not recruited. c.
Subjects did not participant in the survey and data collection despite being reminded 3 times within the last 2 weeks. d. Intervention package includes: 1)
healthy lifestyle education; 2) drug therapies; 3) adherence support. e. Usual care refers to health care following routine procedures at the discretion of
individual family doctors. f. Subjects died from reasons other than coronary heart disease or stroke during the 12 months were excluded. g. Missing cases:
those who had been absent in a consecutive of 6 months or two follow-up appointments at quarterly basis.
https://doi.org/10.1371/journal.pone.0183169.g001
Comprehensive intervention package for hypertension and diabetes in China
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control arm (0.9% and 0.3% respectively) (OR = 9.53, 95% CI: 6.84 to 13.28, P<0.001 and
OR = 18.93, 95% CI: 10.55 to 33.97, P<0.001).
Adding all participants together, 72% took at least one antihypertensive medicines. After 12
months, 66% and 65% respectively took medicines containing at least one modern anti-hyper-
tensive drug in the intervention arm and control arm. In addition, 18% and 16% of partici-
pants in the intervention and control arm respectively did not take modern drugs but took
herbal medicines.
Blood pressure
Mean systolic and diastolic blood pressures in the intervention and control arms for all
patients (hypertensive and diabetic) combined at quarterly intervals during the initial 12
months are shown in Fig 4A and 4B). Mean systolic pressure declined from around 136 to 134
mmHg and mean diastolic pressure from around 81 to 80 mmHg in both intervention and
control arms, but there were no significant differences between arms after adjusting for cluster
effects and demographic factors (0.15, 95% CI -0.96 to 1.26, P = 0.79, and 0.52, 95% CI -0.02 to
1.01, P = 0.05, respectively). At baseline, the blood pressure control rate was 75% among all
patients. For antihypertensive patients, blood pressure was controlled in 60% of hypertensive
Fig 2. Proportions of prescribing and taking of medicines among recruited hypertensive patients*. (A) Proportion of patients having two anti-
hypertensive drugs prescribed and taken in the intervention group; (B) Proportion of patients having two anti-hypertensive drugs prescribed and taken in the
control group; (C) Proportion of patients having aspirin and statin prescribed and taken in the intervention group; (D) Proportion of patients having aspirin
and statin prescribed and taken in the control group. * At 12 months follow-up (quarter 4) compared to the control arm in the intervention arm a significantly
higher proportion of patients had been prescribed (OR = 3.55, 95% CI: 3.31 to 3.80, P<0.001), but had not taken (OR = 1.06, 95% CI: 0.98 to 1.14, P = 0.15),
two antihypertensives; a significantly higher proportion of patients had been prescribed (OR = 565.77, 95% CI: 469.12 to 682.33, P<0.001) and had taken
(OR = 8.85, 95% CI: 7.37 to 10.63, P<0.001), aspirin; and a significantly higher proportion of patients had been prescribed (OR = 656.24, 95% CI: 523.36 to
822.85, P<0.001) and had taken (OR = 11.79, 95% CI: 8.76 to 15.87, P<0.001) statins. Comparisons based on multivariate logistic mixed-effects models,
adjusted for cluster effects, baseline measurement and demographic/socioeconomic factors.
https://doi.org/10.1371/journal.pone.0183169.g002
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patients in the intervention arm and 64% in the control arm at baseline, rising to 75% and 78%
respectively at 12 months (S1 Fig). However, these differences were not statistically significant
at 12 months (OR = 1.07, 95% CI: 0.73 to 1.57, P = 0.74).
Intermediate outcomes at 12 months in the panel sub-group
Baseline characteristics. Demographic and clinical characteristics of the 1,058 patients in
intervention and control clusters who participated in the panel sample are shown in Table 2.
The panel population were relatively less likely to be married (88.1% in the panel compared to
98.3% in the main trial population), relatively poorer (per capita annual income RMB 9,791/
USD 1,632 in the panel compared to RMB 12,900 / USD 2,150 in the main trial population),
and a higher proportion of the panel population had hypertension (74.7%) compared with that
of the general participants (63.9%). However, there were no substantial imbalances regarding
key clinical characteristics between arms in the panel population. At 12 months, 440 (84%) in
the intervention clusters and 510 (95%) in the control clusters were successfully followed up
and included in the analysis (Fig 1).
Fig 3. Proportions of prescribing and taking of medicines among recruited patients with diabetes only*. (A) Proportion of patients having one anti-
hypertensive drug prescribed and taken in the intervention group; (B) Proportion of patients having one anti-hypertensive drug prescribed and taken in the
control group; (C) Proportion of patients having aspirin and statin prescribed and taken in the intervention group; (D) Proportion of patients having aspirin
and statin prescribed and taken in the control group. * At 12 months follow-up (quarter 4) compared to the control arm in the intervention arm a significantly
higher proportion of patients had been prescribed (OR = 11.41,95% CI:10.24 to 12.71, P<0.001), but had not taken (OR = 0.98, 95% CI: 0.89 to 1.07,
P = 0.60), one anti-hypertensive; a significantly higher proportion of patients had been prescribed (OR = 806.98, 95% CI: 597.55 to 1089.79, P<0.001) and
had taken (OR = 9.53, 95% CI: 6.84 to 13.28, P<0.001) aspirin; and a significantly higher proportion of patients had been prescribed (OR = 360.86, 95% CI:
282.59 to 460.81, P<0.001) and had taken (OR = 18.93, 95% CI: 10.55 to 33.97, P<0.001) statins. Comparisons based on multivariate logistic mixed-effects
models, adjusted for cluster effects, baseline measurement and demographic/socioeconomic factors.
https://doi.org/10.1371/journal.pone.0183169.g003
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Drug adherence, lifestyle and changes in intermediate outcomes
At 12 months, good drug adherence was reported by 66% of participants in the intervention
arm, compared with 47% for the control arm (P<0.001, OR = 2.23, 95% CI: 1.701 to 2.932).
Smoking rates were significantly reduced in the intervention arm (4% reduction absolute.
Throughout this section changes are given in absolute terms) compared with the control arm
(2.5% increase) (OR = 0.23, 95% CI: 0.07 to 0.78, P = 0.02, see Table 3). In addition, more
Fig 4. Blood pressure changes (mmHg) by quarter for patients recruited in the trial*. (A) Quarterly changes in mean systolic blood pressure in the
intervention and the control group; (B) Quarterly changes in mean diastolic blood pressure in the intervention and the control group. *No significant
differences between intervention and control arms by 12 months follow-up (quarter 4) in terms of either systolic blood pressure (0.15, 95% CI: -0.96 to 1.26,
P = 0.79, ICC = 0.07) or diastolic blood pressure (0.52, 95% CI: -0.02 to 1.01, P = 0.05, ICC = 0.04). Comparisons based on multivariate linear mixed-effects
models adjusted for cluster effects, baseline measurements and demographic/socioeconomic factors.
https://doi.org/10.1371/journal.pone.0183169.g004
Table 2. Demographic, socioeconomic and disease characteristics of patients recruited in the panel.
Intervention group
N or mean (% or SD)
Control group
N or mean (% or SD)
Total
N or mean (% or SD)
Number of patients 523 535 1058
Age 65.4 (6.6) 65.8 (6.4) 65.6 (6.5)
Gender
Male 242 (46.3) 237 (44.3) 479 (45.3)
Female 281 (53.7) 298 (55.7) 579 (54.7)
Married 456 (87.2) 476 (89.0) 932 (88.1)
Education
Primary (6 years) 419 (80.1) 402 (75.1) 821 (77.6)
High school (7–12 years) 92 (17.6) 116 (21.7) 208 (19.7)
College and above (12 years) 12 (2.3) 17 (3.2) 29 (2.7)
Annual household income (RMB) 29,009 (62,418) 33,540 (43,625) 31,303 (53,753)
Annual per capita income (RMB) 9,069 (14,956) 10,496 (13,965) 9,791 (14,474)
Hypertension and diabetes diagnoses
Including hypertension 387 (74.0) 403 (75.3) 790 (74.7)
Only diabetes 136 (26.0) 132 (24.7) 268 (25.3)
SD: Standard Deviation, RMB: Renminbi at the rate of 1USD = 6RMB in 2013/14
https://doi.org/10.1371/journal.pone.0183169.t002
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patients in the intervention arm took less salt than the control arm (50% vs. 34%, OR = 2.85,
95% CI: 1.12 to 7.27, P = 0.03). Patients in the intervention arm reported drinking less alcohol
and had more exercise (32% vs. 15%, and 31% and 18%, respectively), but these changes were
not statistically significant (P = 0.21 and P = 0.23). Changes in BMI, systolic and diastolic
blood pressure, hemoglobin levels, TC and LDL profiles between baseline and 12 months for
all patients and those with hypertension or diabetes in intervention and control arms are
shown in Table 4. There were not statistically significant, apart from a statistically significantly
Table 3. Lifestyle changes of patients in the panel.
All patients, N (%) Multivariate
analysis
Patients with
hypertension*, N (%)
Multivariate
analysis
Patients with diabetes
only, N (%)
Multivariate
analysis
Intervention Control Odds
ratio
(95% CI)1
p-
value2
Intervention Control Odds
ratio
(95% CI)1
p-
value2
Intervention Control Odds
ratio
(95% CI)1
p-
value2
No. of patients 440 510 324 385 116 125
Smoking
Baseline 81 (18.4) 88
(17.3)
71 (21.9) 69
(17.9)
10 (8.6) 19
(15.2)
12th month 64 (14.5) 101
(19.8)
0.23
(0.07,
0.78)
0.02 53 (16.4) 81
(21.0)
0.21
(0.06,
0.73)
0.01 11 (9.5) 20
(16.0)
0.91
(0.09,
11.5)
0.95
Tried to quit
during last 12
months
21 (32.8) 20
(19.8)
16 (30.2) 14
(17.3)
5 (45.5) 6 (30.0)
Alcohol drinking
Baseline3 98 (22.3) 119
(23.3)
80 (24.8) 88
(22.9)
18 (15.5) 31
(24.8)
12th month 87 (19.8) 131
(25.7)
0.50
(0.17,
1.49)
0.21 68 (21.0) 99
(25.7)
0.50
(0.16,
1.52)
0.21 19 (16.4) 32
(25.6)
0.78
(0.13,
4.76)
0.79
Tried to quit
during last 12
months4
28 (32.2) 15
(12.1)
20 (29.4) 10
(10.4)
8 (42.1) 5 (17.9)
Salt intake compared with baseline
More or no
change
220 (50.0) 336
(65.9)
165 (50.9) 247
(64.1)
55 (47.4) 89
(71.2)
Less 220 (50.0) 174
(34.1)
2.85
(1.12,
7.27)
0.03 159 (49.1) 138
(35.8)
2.29
(0.83,
6.33)
0.11 61 (52.6) 36
(28.8)
3.32
(0.90,
12.2)
0.07
Exercise compared with baseline
More 135 (30.7) 92
(18.0)
105 (32.4) 76
(19.7)
30 (25.9) 16
(12.8)
Less or no
change
305 (69.3) 318
(82.0)
1.90
(0.66,
5.46)
0.23 219 (67.6) 309
(80.3)
1.76
(0.68,
4.52)
0.24, 86 (74.1) 109
(87.2)
3.40
(0.54,
21.4)
0.19
1 Odds ratios comparing intervention to control arm outcomes, their 95% CIs and
2 p-values obtained from multivariate logistic mixed-effects models comparing intervention and control groups, adjusted for cluster effects, baseline
measurements and demographic/socioeconomic factors
3 Missing values were excluded for proportion calculation: 1 (0.2%) missing value in intervention group for all patients; 1 (0.3%) missing value in intervention
group for patients with hypertension
4 Missing values were excluded for proportion calculation: 7 (5.3%) missing values in control group for all patients; 3 (3.0%) missing values in control group
for patients with hypertension; 4 (12.5%) missing values in control group for patients with only diabetes.
*Patients with hypertension include patients with only hypertension and patients with both hypertension and diabetes.
https://doi.org/10.1371/journal.pone.0183169.t003
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Table 4. Changes of metabolic and biomedical indicators of patients in the panel.
All patients, Mean
(SD)
Multivariate
analysis
Patients with
hypertension*, Mean
(SD)
Multivariate
analysis
Patients with
diabetes only, Mean
(SD)
Multivariate
analysis
Intervention Control Mean
difference
(95% CI)1
p-
value2
Intervention Control Mean
difference
(95% CI)1
p-
value2
Intervention Control Mean
difference
(95% CI)1
p-
value2
No. of
patients
440 510 324 385 116 125
BMI
Baseline 24.8 (3.2) 24.0
(3.5)
24.9 (3.2) 24.1
(3.6)
24.6 (3.1) 23.5 (3)
12th
month
24.1 (3.2) 23.8
(3.4)
24.3 (3.3) 23.9
(3.5)
23.8 (3.1) 23.6
(3.1)
Difference -0.7 (2.1) -0.1
(2.7)
0.22 (-0.78,
0.08)
0.11 -0.6 (2.2) -0.2
(2.7)
-0.16
(-0.60,
0.29)
0.49 -0.7 (2.1) 0.4
(2.4)
-0.81
(-1.49,
-0.13)
0.02
SBP
(mmHg)
Baseline 142.6 (17.5) 140.8
(19.1)
145.1 (17.4) 143.1
(19.4)
135.4 (15.8) 133.6
(16.2)
12th
month
141.7 (17.3) 13.5
(17.1)
143.6 (17.8) 140.9
(17.2)
136.3 (14.4) 135.1
(15.8)
Difference -0.9 (22.5) -1.3
(23.3)
-0.73
(-6.80,
5.34)
0.86 -1.5 (23.1) -2.2
(23.2)
0.70 (-6.39,
7.78)
0.84 0.9 (20.8) 1.5
(21.4)
-0.01
(-6.99,
6.97)
0.97
DBP
(mmHg)
Baseline 85.2 (9.4) 84.8
(10.5)
86.7 (9.6) 85.9
(10.7)
81 (7.4) 81.5
(9.2)
12th
month
81.3 (10.4) 82.5
(9.2)
81.9 (10.5) 83 (9.2) 79.6 (9.9) 81 (9.1)
Difference -3.9 (12.9) -2.2
(12.8)
-1.40
(-4.08,
1.29)
0.31 -4.9 (13.2) -2.8
(13.1)
-1.21
(-4.18,
1.76)
0.43 -1.4 (11.7) -0.5
(11.7)
-1.33
(-4.78,
2.11)
0.44
HbA1c (%)
Baseline 6.8 (2.1) 6.5
(2.1)
6.40 (2.1) 6.10
(1.9)
7.10 (2.2) 7.70
(2.4)
12th
month
6.7 (2.1) 7.3
(5.1)
6.60 (1.9) 7.19
(4.9)
7.06 (2.10) 7.69
(5.72)
Difference -0.2 (2.2) 0.8
(5.4)
-0.33
(-1.51,
0.85)
0.56 0.23 (2.2) 1.1
(5.0)
-0.42
(-1.57,
0.73)
0.45 -0.01 (2.17) 0.03
(6.27)
-0.71
(-2.43,
1.01)
0.4
Total cholesterol (mmol/L)
Baseline 4.9 (1.0) 4.9
(1.0)
4.9 (1.0) 4.9
(1.0)
4.9 (0.9) 4.8
(0.8)
12th
month
4.6 (1.0) 4.5
(1.0)
4.5 (1.0) 4.5
(1.0)
4.7 (1) 4.6
(0.9)
Difference -0.4 (1.2) -0.3
(1.2)
0.03 (-0.17,
0.22)
0.78 -0.4 (1.3) -0.4
(1.3)
0.01 (-0.22,
0.24)
0.94 -0.2 (1) -0.2 (1) -0.01
(-0.23,
0.23)
0.98
LDL (mmol/
L)
Baseline 2.8 (0.8) 2.6
(0.7)
2.8 (0.8) 2.6
(0.7)
2.8 (0.7) 2.6
(0.6)
(Continued )
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greater 12 month-baseline decrease in BMI for patients with diabetes only compared in the
intervention arm compared to the control arm (-0.81, 95% CI: -1.49 to -0.13, P = 0.02).
Discussion
This is, to our knowledge, the first pragmatic randomized controlled trial that implements a
comprehensive package at the primary healthcare level for high CVD risk hypertensive or dia-
betic patients. Though in many developed countries some of our CVD risk prevention package
is now standard care, in China and most LMICs it is not generally provided. Within the frame-
work of this trial, we conducted an analysis which showed that interventions were delivered
and that these were signs of improvement at 12-months. The primary indicator (CVD events)
will be analysed at the end of the trial.
A high proportion of patients in the intervention arm were given prescriptions of the anti-
hypertensive drugs, a statin and aspirin, as recommended in the standard medication package
[25]. Most family doctors in the intervention arm have changed prescribing behaviour by 12
months, which compares very well with rates for interventions in a systematic review [28].
However, the actual taking of medications according to these prescriptions was low. There was
a modest improvement in the (previously very low) rates of prescribing statins. But the rates of
taking anti-hypertensive drugs were similar between intervention and control arms. This may
be because there was a relatively high level of general anti-hypertensive use at baseline in both
arms (over 70%), and 75% of patients in both arms achieved targeted blood pressure control.
This high drug uptake at baseline may limit the anti-hypertensive gain that we hoped for in the
trial, and it was reported that patients were reluctant to switch to or add another anti-hyper-
tensive [21]. Similar positive findings on blood pressure control were observed in urban clinics
in China where patients were managed under primary care facilities [29], but these contrast
with the relatively poor national average [30, 31]. In a pragmatic trial using one anti-hyperten-
sive in a setting with low medicine usage (<7%) in China and India, only 20% of participants
took the prescribed medications in 12 months, and this was associated with a small (<3
mmHg) average reduction in systolic blood pressure [32].
We did observe that a higher proportion of patients in the intervention arm took aspirin
and statins compared with the control arm. However, the drug-taken rates were disappointing,
around 10%, compared to that approximately 90% of patients were prescribed aspirin and
Table 4. (Continued)
All patients, Mean
(SD)
Multivariate
analysis
Patients with
hypertension*, Mean
(SD)
Multivariate
analysis
Patients with
diabetes only, Mean
(SD)
Multivariate
analysis
Intervention Control Mean
difference
(95% CI)1
p-
value2
Intervention Control Mean
difference
(95% CI)1
p-
value2
Intervention Control Mean
difference
(95% CI)1
p-
value2
12th
month
2.6 (0.7) 2.6
(0.8)
2.6 (0.7) 2.6
(0.8)
2.7 (0.6) 2.7
(0.7)
Difference -0.2 (0.9) 0 (0.9) -0.06
(-0.24,
0.12)
0.53 -0.2 (0.9) 0 (1.0) -0.05
(-0.25,
0.15)
0.58 -0.1 (0.7) 0.1
(0.8)
-0.07
(-0.29,
0.15)
0.57
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HbA1c = glycosylated hemoglobin; LDL = low-density lipoprotein
1 Mean differences in 12 month-baseline differences between intervention and control arm outcomes, their 95% CIs and
2 p-values obtained from linear mixed-effect models comparing intervention and treatment groups, adjusted for cluster effects, baseline measurements and
demographic/socioeconomic factors.
*Patients with hypertension include patients with only hypertension and patients with both hypertension and diabetes.
https://doi.org/10.1371/journal.pone.0183169.t004
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statins during consultations. We felt that the gap may be that doctors, who identified the low
drug-taken during consultation, were reluctant to persuade patients for a number of reasons.
The worry for aspirin was related to fears of gastrointestinal bleeding [10], while the concern
of statins may be economic. Statins cost over 120 RMB/ USD 20 per month, but only 30% of
drug costs were covered by health insurance [21]. Patient education on these two drugs have
to come from a variety of sources, including their experience of consultations with doctors
from big hospitals and public educations. This is a potential area to be improved. In addition,
a fixed combination pill is not available in China, though this might improve drug taking
adherence compared with separate pills [16].
There were several strengths to this study. First, the intervention was developed with the
provincial health authorities according to the ‘embedded research and development’ approach,
where research questions are focused on local opportunities for going to scale; interventions
are designed and evaluated in real-world setting with public health agencies, and the results
can directly inform program development [33]. Our trial was designed to be implementable,
replicable and sustainable within the routine health services, and supported government policy
on essential public health interventions. The intervention package was embedded into daily
primary care practice [24]. Second, the intervention package and the research procedures were
tested and refined in a pilot study before the trial [21]. Third, the sample was large and patients
were managed on the basis of their CVD risk rather than just treatment of their hypertension
and/or diabetes.
Several limitations need to be stated. First, this was a pragmatic trial implemented by pri-
mary care staff who received half-day training annually and referesh training monthly within
their own hospitals. More intensive training may be needed to target doctor-patient communi-
cation regarding the benefits of using combination medications and changing to healthier life-
styles. Second, we relied on routine reporting systems and inevitably there were missing data.
Patient lifestyle indicators were self-reported. We have provided training for doctors in both
arms regarding standard measurement and consultation reports [22]. Third, the study did not
show any significantly improvement of biomedical indicators regarding blood pressures, BMI,
HbA1c, total cholesterol and LDL between baseline and 12 months in the intervention arm
compared with the control arm, though there is strong evidence that the four-drug combina-
tion is associated with improvements in intermediate outcomes and a marked reduction in
CVD events [15, 16]. This may be due to relatively high uptake of antihypertensive in both
arms at baseline, and low uptake of aspirin and statin in the intervention arm during the inter-
vention. To be of notice, all our medications were not supplied free-of-cost, but were pre-
scribed in routine practice with partial reimbursement through health insurance schemes.
Although countries like China have implemented universal health coverage, health insurance
covers only a marginal part of outpatient costs, and this can substantially reduce the uptake of
more expensive drugs such as statins. The rural health insurance needs to improve its outpa-
tient reach to cover statins and other highly effective medications. Fourth, there was no blind-
ing for healthcare providers or patients, although the outcome analysis was blinded. Fifth, the
trial was not designed and powered to test the effects of individual components within the
comprehensive intervention package. Sixth, we used complete case analyses which may intro-
duce bias into the results depending on the missing data mechanism.
Several programmatic and policy implications can be drawn from this trial. First, the trial
has demonstrated that the essential public health policy, with operational components devel-
oped in the design of the trial, is feasible and implementable with minimum input. Though the
health gains in the first 12 months are modest due to both practice and policy factors, they
may be substantial at the population level when we revisit these indicators as well as CVD
events after a longer follow-up period. Policy makers need to consider raising coverage for
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essential medicines for hypertension and diabetes during for outpatient consultations in pri-
mary care facilities, so that patients can be effectively treated in communities and costlier CVD
events are prevented. And innovative patient education is clearly needed. There has been
strong ownership and involvement of the health authorities, so the comprehensive package
will be ready for scale-up if proven successful later.
Conclusions
The comprehensive intervention package, designed to be replicable within context, was feasi-
ble, and implemented as planned by routine health staff. Additional measures, such as more
intensive training of doctors, innovative patient education and improved health insurance
cover for outpatients are needed. Intervention packages such as this are necessary to ensure
quality improvements in primary health facilities regarding CVD risk, hypertension and diabe-
tes care in China and elsewhere.
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